NBT Bank’s Cytokinetics CYTK Stock Holding History

NBT Bank’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.45K	Hold	17	–	–	﹤0.01%	920
2026 Q1	$1.12K	Buy	+17	New	+$1.08K	﹤0.01%	922

Other funds holding CYTK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

NBT Bank's CYTK Position: Q2 2026 in Review

NBT Bank held its Cytokinetics (CYTK) position steady in Q2 2026 at 17 shares worth $1.45K. The position accounts for ﹤0.01% of the portfolio, ranked #920.

NBT Bank first reported a position in CYTK in Q1 2026 and has held it in 2 quarters since. 483 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

NBT Bank held 17 shares of Cytokinetics worth $1.45K as of Q2 2026.
NBT Bank left its Cytokinetics share count unchanged in Q2 2026.
Cytokinetics made up ﹤0.01% of NBT Bank's portfolio in Q2 2026, its #920 holding.
NBT Bank first reported a position in Cytokinetics in Q1 2026 and has held it in 2 quarters since.
483 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on NBT Bank's 13F filing for Q2 2026, filed 29 Jul 2026.